Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | MAOA | P21397 | 2/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | HTR2B | P41595 | 2/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21583913 | 1.00 | PNMT (0.60) | PNMTTAAR1SLC6A2MAOASIGMAR1 | |
| SCHEMBL30174362 | 1.00 | PNMT (0.60) | PNMTTAAR1SLC6A2MAOASIGMAR1 | |
| SCHEMBL30457687 | 1.00 | PNMT (0.60) | PNMTTAAR1SLC6A2MAOASIGMAR1 | |
| Hydrochloric Acid SCHEMBL5234146 | 0.98 | PNMT (0.58) | PNMTTAAR1SLC6A2MAOASIGMAR1 | |
| Hydrochloric Acid SCHEMBL30559563 | 0.98 | PNMT (0.58) | PNMTTAAR1SLC6A2MAOASIGMAR1 | |
| SCHEMBL1513595 | 0.85 | SIGMAR1 (0.53) | TAAR1SIGMAR1IDO1AGXT | |
| SCHEMBL30138659 | 0.85 | SIGMAR1 (0.53) | TAAR1SIGMAR1IDO1AGXT | |
| SCHEMBL24152546 | 0.84 | TAAR1 (0.73) | PNMTTAAR1SLC6A2MAOASIGMAR1 | |
| SCHEMBL13387614 | 0.84 | TAAR1 (0.73) | PNMTTAAR1SLC6A2MAOASIGMAR1 | |
| SCHEMBL15487598 | 0.83 | TAAR1 (0.46) | PNMTTAAR1SLC6A2MAOASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | claimed |
| CN-113963184-A | Method for evaluating similarity of laser point cloud scene | 杭州大数云智科技有限公司 | 2022-01-21 | — | — | CN | claimed |
| CN-121226008-A | Bismuth ferrite-barium titanate-based energy storage material for pulse power element of new energy automobile electric control system and preparation method | 常州大学 | 2025-12-30 | — | — | CN | disclosed |
| US-12459877-B1 | Recyclable catalyst for carbon dioxide capture | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-11-04 | — | — | US | disclosed |
| CN-120166337-A | Vibration device and device comprising a vibration device | 乐金显示有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-113735672-B | Preparation method of fully substituted 1-butene-3-alkyne derivative | 昆明理工大学 | 2025-01-21 | — | — | CN | disclosed |
| CN-118450787-A | Piezoelectric device and apparatus including the same | 乐金显示有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-118284305-A | Piezoelectric device and apparatus including the same | 乐金显示有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4371977-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| WO-2013040790-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| CN-1694870-A | Acetyl 2-hydroxy-1, 3-diaminoalkanes | PHARMACIA & UPJOHN CO LLC (US) | 2005-11-09 | — | — | CN | disclosed |
| EP-1177175-A2 | HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS PDE 4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000068198-A2 | HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS PDE 4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2000-11-16 | — | — | WO | disclosed |
| US-4857553-A | SIDE EFFECT REDUCTION | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-08-15 | — | — | US | disclosed |
| EP-0302757-A2 | Anti-emetic serotonin depleting agents | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | GPER1, ESR1, ESRRA | PNMT 2191/4885TAAR1 511/4885SLC6A2 2195/4885 |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, HCCS, DHX15 | PNMT 4271/4885TAAR1 2895/4885SLC6A2 4575/4885 |
| US-12459877-B1 | Recyclable catalyst for carbon dioxide capture | SCO2, TELO2, HAO2 | PNMT 3469/4885TAAR1 514/4885SLC6A2 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.